These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23689764)

  • 1. Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer.
    Daskivich TJ; Fan KH; Koyama T; Albertsen PC; Goodman M; Hamilton AS; Hoffman RM; Stanford JL; Stroup AM; Litwin MS; Penson DF
    Ann Intern Med; 2013 May; 158(10):709-17. PubMed ID: 23689764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of long-term other-cause mortality in men with early-stage prostate cancer: results from the Prostate Cancer Outcomes Study.
    Daskivich TJ; Fan KH; Koyama T; Albertsen PC; Goodman M; Hamilton AS; Hoffman RM; Stanford JL; Stroup AM; Litwin MS; Penson DF
    Urology; 2015 Jan; 85(1):92-100. PubMed ID: 25261048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comorbidity and competing risks for mortality in men with prostate cancer.
    Daskivich TJ; Chamie K; Kwan L; Labo J; Dash A; Greenfield S; Litwin MS
    Cancer; 2011 Oct; 117(20):4642-50. PubMed ID: 21480201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weighted versus unweighted Charlson score to predict long-term other-cause mortality in men with early-stage prostate cancer.
    Daskivich TJ; Kwan L; Dash A; Greenfield S; Litwin MS
    Eur Urol; 2014 Dec; 66(6):1002-9. PubMed ID: 24924554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Age Adjusted Comorbidity Index to Predict Long-Term, Other Cause Mortality in Men with Prostate Cancer.
    Daskivich TJ; Kwan L; Dash A; Saigal C; Litwin MS
    J Urol; 2015 Jul; 194(1):73-8. PubMed ID: 25623745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of comorbidity on survival among men with localized prostate cancer.
    Albertsen PC; Moore DF; Shih W; Lin Y; Li H; Lu-Yao GL
    J Clin Oncol; 2011 Apr; 29(10):1335-41. PubMed ID: 21357791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of aggressive versus nonaggressive treatment among men with early-stage prostate cancer and differing comorbid disease burdens at diagnosis.
    Daskivich TJ; Lai J; Dick AW; Setodji CM; Hanley JM; Litwin MS; Saigal C;
    Cancer; 2014 Aug; 120(16):2432-9. PubMed ID: 24824511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer.
    Daskivich TJ; Lai J; Dick AW; Setodji CM; Hanley JM; Litwin MS; Saigal C;
    Cancer; 2014 Dec; 120(23):3642-50. PubMed ID: 25042117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matching tumor risk with aggressiveness of treatment in men with multiple comorbidities and early-stage prostate cancer.
    Daskivich TJ; Chamie K; Kwan L; Dash A; Greenfield S; Litwin MS
    Cancer; 2013 Oct; 119(19):3446-53. PubMed ID: 23861016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
    Sweat SD; Bergstralh EJ; Slezak J; Blute ML; Zincke H
    J Urol; 2002 Aug; 168(2):525-9. PubMed ID: 12131302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer Specific Mortality in Men Diagnosed with Prostate Cancer before Age 50 Years: A Nationwide Population Based Study.
    Thorstenson A; Garmo H; Adolfsson J; Bratt O
    J Urol; 2017 Jan; 197(1):61-66. PubMed ID: 27328367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Questioning the 10-year Life Expectancy Rule for High-grade Prostate Cancer: Comparative Effectiveness of Aggressive vs Nonaggressive Treatment of High-grade Disease in Older Men With Differing Comorbid Disease Burdens.
    Daskivich TJ; Lai J; Dick AW; Setodji CM; Hanley JM; Litwin MS; Saigal C;
    Urology; 2016 Jul; 93():68-76. PubMed ID: 27079130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
    Aizer AA; Chen MH; Hattangadi J; D'Amico AV
    BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Competing-risks mortality after radiotherapy vs. observation for localized prostate cancer: a population-based study.
    Abdollah F; Sun M; Schmitges J; Thuret R; Tian Z; Shariat SF; Briganti A; Jeldres C; Perrotte P; Montorsi F; Karakiewicz PI
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):95-103. PubMed ID: 22330991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis.
    Briganti A; Spahn M; Joniau S; Gontero P; Bianchi M; Kneitz B; Chun FK; Sun M; Graefen M; Abdollah F; Marchioro G; Frohenberg D; Giona S; Frea B; Karakiewicz PI; Montorsi F; Van Poppel H; Jeffrey Karnes R;
    Eur Urol; 2013 Apr; 63(4):693-701. PubMed ID: 22959192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Competing Risks of Mortality among Men with Biochemical Recurrence after Radical Prostatectomy.
    Daskivich TJ; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Klaassen Z; Terris MK; Freedland SJ
    J Urol; 2020 Sep; 204(3):511-517. PubMed ID: 32243242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Low-Dose Aspirin and Mortality After Prostate Cancer Diagnosis: A Nationwide Cohort Study.
    Skriver C; Dehlendorff C; Borre M; Brasso K; Larsen SB; Dalton SO; Nørgaard M; Pottegård A; Hallas J; Sørensen HT; Friis S
    Ann Intern Med; 2019 Apr; 170(7):443-452. PubMed ID: 30831581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-Reported Health Status Predicts Other-Cause Mortality in Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study.
    Hoffman RM; Koyama T; Albertsen PC; Barry MJ; Daskivich TJ; Goodman M; Hamilton AS; Stanford JL; Stroup AM; Potosky AL; Penson DF
    J Gen Intern Med; 2015 Jul; 30(7):924-34. PubMed ID: 25678374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen Deprivation Therapy Use in the Setting of High-dose Radiation Therapy and the Risk of Prostate Cancer-Specific Mortality Stratified by the Extent of Competing Mortality.
    Rose BS; Chen MH; Wu J; Braccioforte MH; Moran BJ; Doseretz DE; Katin MJ; Ross RH; Salenius SA; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(4):778-784. PubMed ID: 27788950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.